Differing Risks of Occlusive Retinal Vasculitis with Concurrent Intraocular Inflammation Among Intravitreal Antivascular Endothelial Growth Factor Therapies
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Retina (Philadelphia, Pa.) - 41(2021), 4 vom: 01. Apr., Seite 669-670 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schmidt-Ott, Ursula [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
15C2VL427D |
|---|
| Anmerkungen: |
Date Completed 22.11.2021 Date Revised 16.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/IAE.0000000000003015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317330578 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317330578 | ||
| 003 | DE-627 | ||
| 005 | 20231225163036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/IAE.0000000000003015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1057.xml |
| 035 | |a (DE-627)NLM317330578 | ||
| 035 | |a (NLM)33165295 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schmidt-Ott, Ursula |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differing Risks of Occlusive Retinal Vasculitis with Concurrent Intraocular Inflammation Among Intravitreal Antivascular Endothelial Growth Factor Therapies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.11.2021 | ||
| 500 | |a Date Revised 16.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 650 | 7 | |a aflibercept |2 NLM | |
| 650 | 7 | |a 15C2VL427D |2 NLM | |
| 650 | 7 | |a Receptors, Vascular Endothelial Growth Factor |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a brolucizumab |2 NLM | |
| 650 | 7 | |a XSZ53G39H5 |2 NLM | |
| 700 | 1 | |a Hughes, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Reed, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Leal, Sérgio |e verfasserin |4 aut | |
| 700 | 1 | |a Amer, Fouad |e verfasserin |4 aut | |
| 700 | 1 | |a Moini, Hadi |e verfasserin |4 aut | |
| 700 | 1 | |a Bussfeld, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Vitti, Robert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Retina (Philadelphia, Pa.) |d 1981 |g 41(2021), 4 vom: 01. Apr., Seite 669-670 |w (DE-627)NLM012598550 |x 1539-2864 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:4 |g day:01 |g month:04 |g pages:669-670 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/IAE.0000000000003015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 4 |b 01 |c 04 |h 669-670 | ||